In what’s being described as a major breakthrough for inherited forms of breast cancer, researchers from the University of Cambridge have reported a 100% three-year survival rate for patients given a new type of pre-surgical treatment. The study, recently published in Nature Communications, focused on women with aggressive early-stage breast cancers linked to BRCA1 or BRCA2 mutations—genes that greatly increase the risk of developing certain cancers. The results have been hailed as “game-changing” for a group of patients who are often faced with particularly tough treatment options and higher relapse rates.
Led by Professor Jean Abraham, the trial, called the PARTNER study, used a combination of standard chemotherapy and a drug called olaparib, a PARP inhibitor designed to block cancer cells from repairing their own DNA. What made this trial different wasn’t just the treatment itself, but when it was given. Instead of waiting until after surgery to introduce olaparib, researchers administered it during a carefully timed window before surgery, right after chemotherapy. This new timing appears to have made all the difference.
The trial involved 48 patients in total, but the most notable results came from the 39 who received this new combined approach. All of them were still alive three years after treatment, with only one person experiencing a recurrence. That kind of outcome is rarely seen in studies of aggressive breast cancers, particularly among those with BRCA mutations, which are notoriously difficult to treat and carry a high risk of relapse. By comparison, three-year survival rates in similar patient groups using standard treatment are usually closer to 88%.
How this treatment works, and why timing matters
To understand why this new treatment worked so well, it helps to know a bit about what BRCA genes do. In healthy cells, BRCA1 and BRCA2 play a role in repairing damaged DNA. But when these genes are mutated, the repair process breaks down, and the risk of developing cancer rises dramatically. Around one in fifty breast cancer cases involve a BRCA mutation, but the number jumps significantly for women diagnosed before the age of 45.
PARP inhibitors like olaparib are designed to exploit this flaw. They prevent cancer cells from patching up their own DNA damage, essentially overwhelming the cell’s survival mechanisms and causing it to die off. These drugs are already licensed for use after surgery in BRCA-related breast cancers, but this study tested whether moving them earlier in the treatment process could yield even better results.
The team gave patients a round of chemotherapy first, then paused for 48 hours to let healthy cells, especially bone marrow, recover slightly, before introducing olaparib for a 12-week course. After that, patients underwent surgery as usual. That short pause was key. In earlier trials, combining chemotherapy and PARP inhibitors had caused serious side effects, largely because both suppress bone marrow. By spacing the drugs out just enough, the team was able to avoid most of these risks while still delivering a one-two punch to the tumour.
What followed was striking. Not only did the tumours shrink significantly, but in many cases, they disappeared entirely. Pathologists found that over half of the women in the trial had a “pathological complete response,” meaning no signs of cancer were left in the tissue removed during surgery. Those who didn’t achieve that complete response still had positive outcomes, showing that the treatment had made the tumours more vulnerable to follow-up care.
Professor Abraham called the results “extremely encouraging” and suggested they could lead to a rethink of how inherited breast cancers are treated. She also pointed out that this kind of precision-timed therapy could be extended to other cancers linked to BRCA mutations pending further trials.
The human impact, and what happens next
For patients like Jackie Van Bochoven, a 59-year-old woman who joined the PARTNER trial after being diagnosed with BRCA1-related breast cancer, the treatment has meant more than just remission. It gave her peace of mind. Jackie was told her cancer was aggressive and had spread to her lymph nodes. But six years on, she remains cancer-free and is back at work, spending time with family, and speaking openly about how important the trial was to her. “It gave me more time with my loved ones,” she said. “It gave me my life back.”
The results have also prompted fresh conversations about access and rollout. Although olaparib is already approved for use in the NHS post-surgery, giving it before surgery would represent a shift in standard care. Researchers now plan to expand the trial to a larger group of patients and work with healthcare providers to explore how this approach could be introduced more widely. If follow-up studies confirm the findings, it could reshape treatment pathways for people with inherited forms of cancer, offering faster, more targeted care with fewer side effects.
The PARTNER study also fits into a broader move toward smarter, biology-driven cancer treatment. Instead of applying a one-size-fits-all model, oncologists are increasingly looking for ways to personalise care based on tumour type, genetic profile, and the body’s response to specific combinations of treatment. Similar breakthroughs are already underway in other areas, including targeted antibody-drug conjugates for triple-negative breast cancer and newer hormone therapies for HER2-low tumours. But what makes this study stand out is its simplicity and the dramatic nature of the results.
While researchers are careful not to overpromise based on one small trial, the fact that no patients in the olaparib group died within three years, and that only one relapsed, has given real cause for optimism. If this can be repeated on a larger scale, it could offer a new lifeline for people who’ve long been told their cancer is harder to treat.